Press Releases

News

Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study

An innovative vaccine therapy developed at Roswell Park Cancer Institute is being tested in a multisite clinical trial involving 50 patients with newly diagnosed glioblastoma brain tumors. The phase II study, now accruing patients at both Roswell Park and the Cleveland Clinic, will assess the effectiveness of the SurVaxM vaccine in combination with standard chemotherapy as treatment for this often-fatal cancer.
News

Roswell Park Experts Assess Role of Fallopian-Tube Surgery in Ovarian Cancer Prevention

Identifying patients at increased risk for ovarian cancer is key to prevention, early detection and ultimately improved survival. In a new article for the American Medical Association Journal of Ethics, two Roswell Park Cancer Institute physicians review the state of the science regarding the surgical removal of the fallopian tubes as an option to reduce the risk of the disease.
News

Kunle Odunsi, MD, Invited to Present at Prestigious FDA Ovarian Cancer Endpoints Workshop

The U.S. Food and Drug Administration (FDA) is hosting an Ovarian Cancer Endpoints Workshop with presentations by the Society of Gynecologic Oncology, the American Association for Cancer Research and the American Society of Clinical Oncology, along with invited guest speakers, including Deputy Director of Roswell Park, Kunle Odunsi, MD, PhD, FRCOG, FACOG.
News

Ovarian Cancer Survival Influenced by History of Oral Contraceptive Use

A history of oral contraceptive use and having at least one child increased longevity by nearly three years in patients diagnosed with ovarian cancer, according to a Roswell Park Cancer Institute study recently published online ahead of print in the International Journal of Gynecological Cancer.